Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:secondary carboxamide
go back to main search page
Accession:CHEBI:140325 term browser browse the term
Definition:A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
Synonyms:related_synonym: Formula=CHNOR2;   SMILES=N(C(*)=O)(*)[H];   secondary carboxamides


show annotations for term's descendants           Sort by:
 
acetoacetyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 affects binding ISO acetoacetyl CoA binds to HSD17B2 protein CTD PMID:25526675 NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
JBrowse link
acetyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acly ATP citrate lyase increases abundance ISO ACLY protein results in increased abundance of Acetyl Coenzyme A CTD PMID:28077572 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G App amyloid beta precursor protein affects localization
increases secretion
multiple interactions
ISO APP protein affects the localization of Acetyl Coenzyme A
Acetyl Coenzyme A results in increased secretion of APP protein modified form
Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]
CTD PMID:16122837, PMID:22906069 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Crat carnitine O-acetyltransferase decreases activity EXP Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein CTD PMID:8075222 NCBI chr 3:8,967,984...8,981,959
Ensembl chr 3:8,968,417...8,981,362
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor decreases abundance
multiple interactions
ISO ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A
3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]
CTD PMID:25440059 NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] CTD PMID:16122837 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Kat2b lysine acetyltransferase 2B affects binding ISO Acetyl Coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:4,440,982...4,492,949 JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator multiple interactions ISO METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] CTD PMID:30213948 NCBI chr10:110,893,261...110,907,256
Ensembl chr10:110,893,232...110,907,243
JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions
affects binding
ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein]
Acetyl Coenzyme A binds to NAT1 protein
CTD PMID:20545351, PMID:22835378 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
acryloyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Echs1 enoyl-CoA hydratase, short chain 1 increases abundance ISO ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
JBrowse link
G Hibch 3-hydroxyisobutyryl-CoA hydrolase increases abundance ISO HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 9:53,446,185...53,526,727
Ensembl chr 9:53,446,194...53,526,728
JBrowse link
afatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egf epidermal growth factor multiple interactions ISO afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein]; afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein] CTD PMID:28787001 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor decreases activity
decreases phosphorylation
ISO afatinib results in decreased activity of EGFR protein; afatinib results in decreased activity of EGFR protein mutant form
afatinib results in decreased phosphorylation of EGFR protein
CTD PMID:21322567, PMID:22242139, PMID:28787001 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 multiple interactions ISO afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein] CTD PMID:28787001 NCBI chr20:4,576,033...4,592,980
Ensembl chr20:4,576,057...4,592,980
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta decreases expression ISO afatinib results in decreased expression of IKBKB protein CTD PMID:22242139 NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO Afatinib inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA] CTD PMID:31944254 NCBI chr 1:214,725,482...214,756,653 JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22242139 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Pou5f1 POU class 5 homeobox 1 decreases expression
multiple interactions
ISO afatinib results in decreased expression of POU5F1 protein
afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]
CTD PMID:28787001 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22242139 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
arachidonoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
asperphenamate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ctsl cathepsin L multiple interactions ISO asperphenamate analog binds to and results in decreased activity of CTSL protein CTD PMID:30253340 NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
JBrowse link
G Ctss cathepsin S multiple interactions ISO asperphenamate analog binds to and results in decreased activity of CTSS protein CTD PMID:30253340 NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
JBrowse link
butyryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kat2b lysine acetyltransferase 2B affects binding ISO butyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:4,440,982...4,492,949 JBrowse link
dacomitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egfr epidermal growth factor receptor multiple interactions ISO dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] CTD PMID:27491023 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
decanoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein CTD PMID:25526675 NCBI chr 5:76,812,881...76,848,853
Ensembl chr 5:76,812,931...76,848,101
JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:79,601,937...79,630,547
Ensembl chr 9:79,601,901...79,630,536
JBrowse link
glutaryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acot4 acyl-CoA thioesterase 4 affects hydrolysis ISO ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A CTD PMID:16141203 NCBI chr 6:107,517,668...107,522,952
Ensembl chr 6:107,517,668...107,522,952
JBrowse link
G Acot8 acyl-CoA thioesterase 8 affects hydrolysis ISO ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A CTD PMID:16141203 NCBI chr 3:161,260,837...161,272,495
Ensembl chr 3:161,259,735...161,272,460
JBrowse link
glycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of glycolithocholic acid CTD PMID:25061560 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of glycolithocholic acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
glycoursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Edn1 endothelin 1 decreases expression ISO glycoursodeoxycholic acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions ISO [glycoursodeoxycholic acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form CTD PMID:18188457 NCBI chr 4:7,264,677...7,282,355
Ensembl chr 4:7,264,683...7,281,223
JBrowse link
G Tp53 tumor protein p53 multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
glycyl-L-phenylalanine 2-naphthylamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nox1 NADPH oxidase 1 multiple interactions ISO 1-(3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]; NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]] CTD PMID:24912985 NCBI chr  X:104,909,328...104,932,508
Ensembl chr  X:104,909,326...104,932,508
JBrowse link
hexanoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:79,601,937...79,630,547
Ensembl chr 9:79,601,901...79,630,536
JBrowse link
isobutyryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kat2b lysine acetyltransferase 2B affects binding ISO isobutyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:4,440,982...4,492,949 JBrowse link
lauroyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein CTD PMID:25526675 NCBI chr 5:76,812,881...76,848,853
Ensembl chr 5:76,812,931...76,848,101
JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:79,601,937...79,630,547
Ensembl chr 9:79,601,901...79,630,536
JBrowse link
LGK974 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased expression of BAK1 protein] CTD PMID:30205152 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Casp3 caspase 3 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein] CTD PMID:30205152 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in decreased expression of CCND1 protein] CTD PMID:30205152 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat affects the localization of CTNNB1 protein]; LGK974 inhibits the reaction [Paraquat results in increased expression of and results in decreased phosphorylation of CTNNB1 protein] CTD PMID:30205152 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased transport of DIABLO protein] CTD PMID:30205152 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G Htra2 HtrA serine peptidase 2 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased transport of HTRA2 protein] CTD PMID:30205152 NCBI chr 4:113,883,671...113,886,833
Ensembl chr 4:113,883,670...113,886,994
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased cleavage of PARP1 protein] CTD PMID:30205152 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
malonyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mlycd malonyl-CoA decarboxylase multiple interactions ISO PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] CTD PMID:14641110 NCBI chr19:52,032,950...52,048,773
Ensembl chr19:52,032,886...52,048,753
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] CTD PMID:14641110 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
marimastat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Areg amphiregulin multiple interactions ISO marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of AREG protein] CTD PMID:15342401 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
JBrowse link
G Grp gastrin releasing peptide multiple interactions ISO marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of AREG protein]; marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein] CTD PMID:15342401 NCBI chr18:61,563,458...61,576,818
Ensembl chr18:61,563,053...61,576,818
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions EXP marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK1 protein] CTD PMID:15574683 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK3 protein] CTD PMID:15574683 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK8 protein] CTD PMID:15574683 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO marimastat inhibits the reaction [Oxygen deficiency results in increased expression of MMP2 protein] CTD PMID:22340517 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein] CTD PMID:15342401 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
methacrylyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Echs1 enoyl-CoA hydratase, short chain 1 increases abundance ISO ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A CTD PMID:25125611 NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
JBrowse link
G Hibch 3-hydroxyisobutyryl-CoA hydrolase increases abundance ISO HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A CTD PMID:25125611 NCBI chr 9:53,446,185...53,526,727
Ensembl chr 9:53,446,194...53,526,728
JBrowse link
myristoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Dbi diazepam binding inhibitor, acyl-CoA binding protein affects binding ISO S-tetradecanoyl-coenzyme A binds to DBI protein CTD PMID:17044054 NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
N-(p-amylcinnamoyl)anthranilic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc13a2 solute carrier family 13 member 2 multiple interactions ISO [4-amylcinnamoylanthranilic acid results in decreased activity of SLC13A2 protein] which results in decreased susceptibility to diethylene glycol metabolite CTD PMID:21856646 NCBI chr10:65,664,665...65,692,046
Ensembl chr10:65,664,667...65,692,023
JBrowse link
G Trpm2 transient receptor potential cation channel, subfamily M, member 2 multiple interactions
decreases activity
ISO 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]
4-amylcinnamoylanthranilic acid results in decreased activity of TRPM2 protein
CTD PMID:18204483, PMID:30229906 NCBI chr20:11,434,062...11,482,880
Ensembl chr20:11,436,267...11,482,051
JBrowse link
N-acetyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mthfs methenyltetrahydrofolate synthetase affects binding ISO N-acetyldopamine binds to MTHFS protein CTD PMID:17055997 NCBI chr 8:96,564,877...96,614,386
Ensembl chr 8:96,564,877...96,614,348
JBrowse link
N-benzoyl-L-alanine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ncoa2 nuclear receptor coactivator 2 multiple interactions ISO N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]; N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein] CTD PMID:31566444 NCBI chr 5:5,466,544...5,696,540
Ensembl chr 5:5,616,483...5,694,598
JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein] CTD PMID:31566444 NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
JBrowse link
G Thrb thyroid hormone receptor beta multiple interactions
affects binding
ISO N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein]
N-benzoylalanine binds to THRB protein
CTD PMID:31566444 NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
JBrowse link
N-benzoylglycine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid] CTD PMID:30639138 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO hippuric acid inhibits the reaction [ABCC4 protein results in increased export of Methotrexate] CTD PMID:21483698 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO hippuric acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate] CTD PMID:21483698 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of hippuric acid CTD PMID:24709313 NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
JBrowse link
G Slc10a1 solute carrier family 10 member 1 increases expression ISO hippuric acid results in increased expression of SLC10A1 mRNA CTD PMID:30639138 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
N-Methylolacrylamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acsm1 acyl-CoA synthetase medium-chain family member 1 increases expression ISO N-methylolacrylamide results in increased expression of ACSM1 mRNA CTD PMID:17311802 NCBI chr 1:189,359,374...189,395,277
Ensembl chr 1:189,289,957...189,395,276
JBrowse link
G Ces1d carboxylesterase 1D increases expression ISO N-methylolacrylamide results in increased expression of CES1 mRNA CTD PMID:17311802 NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
JBrowse link
G Ephx1 epoxide hydrolase 1 decreases expression ISO N-methylolacrylamide results in decreased expression of EPHX1 mRNA CTD PMID:17311802 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases activity ISO N-methylolacrylamide results in increased activity of NFE2L2 protein CTD PMID:30114225, PMID:30203046 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO N-methylolacrylamide results in increased expression of NQO1 mRNA CTD PMID:17311802 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases activity ISO N-methylolacrylamide results in decreased activity of STAT5B protein CTD PMID:30114225 NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
JBrowse link
N-oleoyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cnr1 cannabinoid receptor 1 multiple interactions EXP N-oleoyldopamine binds to and results in increased activity of CNR1 protein CTD PMID:12569099 NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions
increases activity
ISO
EXP
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein] CTD PMID:12569099, PMID:15615864 NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
JBrowse link
nilotinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A affects response to substance ISO ABCB1 protein affects the susceptibility to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide CTD PMID:28623111 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc10 ATP binding cassette subfamily C member 10 multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine] CTD PMID:19841739 NCBI chr 9:17,041,351...17,061,263
Ensembl chr 9:17,041,389...17,063,780
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 affects response to substance ISO ABCG2 protein affects the susceptibility to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide CTD PMID:24954033 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
decreases phosphorylation
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein]; [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of ABL1 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein mutant form
CTD PMID:16849647, PMID:19878872, PMID:23883479 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases phosphorylation ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ALDH1A2 mRNA CTD PMID:31711903 NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
JBrowse link
G Ap2m1 adaptor related protein complex 2 subunit mu 1 multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of AP2M1 mRNA CTD PMID:28786057 NCBI chr11:84,041,184...84,047,542
Ensembl chr11:84,041,184...84,047,546
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions
decreases expression
ISO arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ATF6 protein] CTD PMID:23883479 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of BAX protein] CTD PMID:31593741 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of BCL2 protein CTD PMID:26549707 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions
decreases phosphorylation
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of BCR protein mutant form
CTD PMID:16849647, PMID:19878872 NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of CASP3 protein]
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased activity of CASP3 protein
CTD PMID:23707608, PMID:23883479, PMID:26549707, PMID:31593741 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 increases activity
increases cleavage
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased activity of CASP7 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP7 protein
CTD PMID:23707608, PMID:23883479 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp9 caspase 9 increases cleavage ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP9 protein CTD PMID:26549707 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cltc clathrin heavy chain multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of CLTC mRNA CTD PMID:28786057 NCBI chr10:74,014,560...74,070,578
Ensembl chr10:74,014,562...74,070,266
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein decreases phosphorylation
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of CRKL protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of CRKL protein
CTD PMID:19878872, PMID:23883479 NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of DDIT3 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of DDIT3 mRNA]
CTD PMID:23883479 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dnm2 dynamin 2 multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of DNM2 mRNA CTD PMID:28786057 NCBI chr 8:22,458,869...22,540,649
Ensembl chr 8:22,458,899...22,540,524
JBrowse link
G Edem1 ER degradation enhancing alpha-mannosidase like protein 1 increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of EDEM1 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of EDEM1 mRNA]
CTD PMID:23883479 NCBI chr 4:140,886,644...140,918,654
Ensembl chr 4:140,886,545...140,915,779
JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of EYA1 mRNA CTD PMID:31711903 NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
JBrowse link
G Fcer1g Fc fragment of IgE receptor Ig multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of FCER1G mRNA CTD PMID:28786057 NCBI chr13:89,601,894...89,606,326
Ensembl chr13:89,601,896...89,606,326
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS protein
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS protein]
CTD PMID:23883479 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Foxc2 forkhead box C2 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of FOXC2 mRNA CTD PMID:31711903 NCBI chr19:53,044,379...53,047,081
Ensembl chr19:53,044,379...53,047,081
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions
increases expression
ISO arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of GCLM mRNA] CTD PMID:23883479 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Hdc histidine decarboxylase decreases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of HDC mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]
CTD PMID:16849647 NCBI chr 3:119,057,524...119,075,599
Ensembl chr 3:119,057,517...119,075,619
JBrowse link
G Hoxb7 homeo box B7 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HOXB7 mRNA CTD PMID:31711903 NCBI chr10:84,135,224...84,138,642
Ensembl chr10:84,135,116...84,138,637
JBrowse link
G Hoxb9 homeo box B9 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HOXB9 mRNA CTD PMID:31711903 NCBI chr10:84,119,772...84,124,963
Ensembl chr10:84,119,884...84,123,390
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HSPA5 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HSPA5 mRNA]
CTD PMID:23883479 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Il18 interleukin 18 multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of IL18 protein] CTD PMID:31593741 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of IL1B protein] CTD PMID:31593741 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of and results in increased phosphorylation of JUN protein; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN protein
CTD PMID:23883479 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB protein
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB protein]
CTD PMID:23883479 NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased activity of KCNH2 protein CTD PMID:23707608 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Meox1 mesenchyme homeobox 1 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of MEOX1 mRNA CTD PMID:31711903 NCBI chr10:89,797,011...89,817,009
Ensembl chr10:89,797,038...89,816,491
JBrowse link
G Mesp2 mesoderm posterior bHLH transcription factor 2 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of MESP2 mRNA CTD PMID:31711903 NCBI chr 1:141,550,633...141,553,239
Ensembl chr 1:141,550,633...141,553,230
JBrowse link
G Neurog2 neurogenin 2 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of NEUROG2 mRNA CTD PMID:31711903 NCBI chr 2:231,962,517...231,963,441
Ensembl chr 2:231,962,517...231,963,308
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] CTD PMID:21473879 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Olig3 oligodendrocyte transcription factor 3 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of OLIG3 mRNA CTD PMID:31711903 NCBI chr 1:14,797,766...14,799,835
Ensembl chr 1:14,797,766...14,799,835
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein]
CTD PMID:26549707 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pax3 paired box 3 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of PAX3 mRNA CTD PMID:31711903 NCBI chr 9:84,004,004...84,101,226
Ensembl chr 9:84,005,183...84,101,172
JBrowse link
G Pax6 paired box 6 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of PAX6 mRNA CTD PMID:31711903 NCBI chr 3:95,700,241...95,728,682
Ensembl chr 3:95,707,386...95,728,624
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of RELA protein] CTD PMID:31593741 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Sec24b SEC24 homolog B, COPII coat complex component multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of SEC24B mRNA CTD PMID:28786057 NCBI chr 2:230,286,886...230,356,887
Ensembl chr 2:230,287,296...230,356,919
JBrowse link
G Tcf15 transcription factor 15 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of TCF15 mRNA CTD PMID:31711903 NCBI chr 3:147,643,250...147,649,511
Ensembl chr 3:147,643,250...147,649,504
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TGFB1 mRNA] CTD PMID:21473879 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP
ISO
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of TNF protein]
CTD PMID:21473879, PMID:31593741 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfsf12 TNF superfamily member 12 multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of TNFSF12 protein] CTD PMID:31593741 NCBI chr10:56,290,780...56,300,137
Ensembl chr10:56,290,780...56,300,077
JBrowse link
G Tp53 tumor protein p53 increases secretion ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased secretion of TP53 protein CTD PMID:29370077 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases activity ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased activity of UGT1A1 protein CTD PMID:26875642 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Uncx UNC homeobox decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of UNCX mRNA CTD PMID:31711903 NCBI chr12:17,182,158...17,186,679
Ensembl chr12:17,182,163...17,186,679
JBrowse link
G Xbp1 X-box binding protein 1 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of XBP1 mRNA alternative form CTD PMID:23883479 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
oleoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO oleoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO oleoyl-coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
osimertinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein CTD PMID:30145802, PMID:30623574, PMID:30993382 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
ISO Acetylcysteine inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; Vitamin E inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form] CTD PMID:28237877 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions
decreases response to substance
ISO CAT protein inhibits the reaction [osimertinib results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CAT protein results in decreased susceptibility to osimertinib
CTD PMID:28237877 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Egf epidermal growth factor multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein] CTD PMID:30623574 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases activity
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]; osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein
osimertinib results in decreased activity of EGFR protein
CTD PMID:28237877, PMID:30145802, PMID:30623574, PMID:30993382 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO osimertinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Il6 interleukin 6 multiple interactions ISO osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein] CTD PMID:30623574 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK1 protein CTD PMID:30623574, PMID:30993382 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK3 protein CTD PMID:30623574, PMID:30993382 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases expression
increases cleavage
multiple interactions
ISO osimertinib results in increased expression of PARP1 protein modified form
osimertinib results in increased cleavage of PARP1 protein
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]; Vitamin E inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CTD PMID:28237877, PMID:30171258 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Sqstm1 sequestosome 1 decreases expression ISO osimertinib results in decreased expression of SQSTM1 protein CTD PMID:30145802 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of STAT3 protein] CTD PMID:30623574 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases response to substance
multiple interactions
affects response to substance
ISO TWIST1 protein results in decreased susceptibility to osimertinib
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]
TWIST1 protein affects the susceptibility to osimertinib
CTD PMID:30171258, PMID:30993382 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
p-aminohippuric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca8 ATP binding cassette subfamily A member 8 affects transport ISO ABCA8 protein affects the transport of p-Aminohippuric Acid CTD PMID:12379217 NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
JBrowse link
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of p-Aminohippuric Acid CTD PMID:24709313 NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
JBrowse link
G Slc17a3 solute carrier family 17 member 3 affects transport ISO SLC17A3 gene SNP affects the transport of p-Aminohippuric Acid CTD PMID:21282933 NCBI chr17:43,518,760...43,545,160
Ensembl chr17:43,518,655...43,543,185
JBrowse link
G Slc22a12 solute carrier family 22 member 12 multiple interactions
increases uptake
ISO Barium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Diethyl Pyrocarbonate inhibits the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Ouabain promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Potassium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid] CTD PMID:15284287 NCBI chr 1:221,910,787...221,919,277
Ensembl chr 1:221,910,767...221,919,301
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO p-Aminohippuric Acid inhibits the reaction [SLC22A2 protein results in increased uptake of Cimetidine] CTD PMID:15496291 NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
JBrowse link
G Slc22a20 solute carrier family 22 member 20 multiple interactions ISO p-Aminohippuric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate] CTD PMID:16478971 NCBI chr 1:221,327,608...221,344,367
Ensembl chr 1:221,328,711...221,343,889
JBrowse link
G Slc22a6 solute carrier family 22 member 6 affects transport
increases import
increases uptake
multiple interactions
increases export
increases secretion
ISO
EXP
SLC22A6 protein affects the transport of p-Aminohippuric Acid
SLC22A6 protein results in increased import of p-Aminohippuric Acid
SLC22A6 protein results in increased uptake of p-Aminohippuric Acid; SLC22A6 results in increased uptake of p-Aminohippuric Acid
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; 9-((2-phosphonylmethoxy)ethyl)guanine analog inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; adefovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Amitriptyline inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I inhibits the reaction [SLC22A6 results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; bis(4-hydroxyphenyl)sulfone inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol A promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol F promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefaclor inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefdinir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefotiam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftibuten inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftizoxime inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cephaloridine inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Chlorides promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; chlorpyrifos-methyl inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cimetidine inhibits the reaction [SLC22A6 protein affects the transport of p-Aminohippuric Acid]; cyazofamid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Diazepam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fenitrothion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fluorescein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Glutarates promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; glutaric acid promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; Malathion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Mianserin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased susceptibility to [mercuric oxide co-treated with Acetylcysteine]]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid analog]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of 2,4-Dichlorophenoxyacetic Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Uric Acid]; Penicillin G inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Quercetin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Resveratrol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Sulfobromophthalein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Triazolam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid]; Unithiol promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid]
p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of ochratoxin A]; perfluoro-n-heptanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorohexanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorooctanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]
CTD PMID:10336520, PMID:11602689, PMID:12472777, PMID:12606766, PMID:15200431, PMID:15284288, PMID:15496291, PMID:16098483, PMID:17255469, PMID:17353191, PMID:18216144, PMID:19605544, PMID:19643159, PMID:19915082, PMID:21244849, PMID:21256917, PMID:21561794, PMID:23856525, PMID:27377006, PMID:27989701, PMID:28629854, PMID:28890383, PMID:32003934, PMID:32305507 NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
JBrowse link
G Slc22a7 solute carrier family 22 member 7 increases uptake ISO SLC22A7 protein results in increased uptake of p-Aminohippuric Acid CTD PMID:12065749, PMID:15901346, PMID:21256917 NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
JBrowse link
G Slc22a8 solute carrier family 22 member 8 multiple interactions
increases uptake
affects transport
increases export
ISO
EXP
Cimetidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Enalapril inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Ibuprofen inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; tenoxicam inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A8 protein affects the transport of p-Aminohippuric Acid
SLC22A8 results in increased export of p-Aminohippuric Acid
aristolochic acid I promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]; estrone sulfate promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]
p-Aminohippuric Acid inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]
CTD PMID:10224140, PMID:11306713, PMID:15100168, PMID:15319347, PMID:16098483, PMID:19643159 NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
JBrowse link
palmitoyl ethanolamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Apob apolipoprotein B affects folding ISO palmidrol affects the folding of APOB protein CTD PMID:16115474 NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions EXP [rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog CTD PMID:17558434 NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
JBrowse link
G Cnr2 cannabinoid receptor 2 affects binding
multiple interactions
ISO
EXP
palmidrol binds to CNR2 protein
[SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog
CTD PMID:10617657, PMID:10688601, PMID:17558434 NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions EXP palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of GSTA1 protein] CTD PMID:26474837 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Lcn2 lipocalin 2 multiple interactions EXP palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of LCN2 protein] CTD PMID:26474837 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions EXP [MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog CTD PMID:17558434 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
palmitoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acox1 acyl-CoA oxidase 1 increases metabolic processing
multiple interactions
ISO ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A
[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]
CTD PMID:10497882 NCBI chr10:104,724,534...104,748,003
Ensembl chr10:104,722,958...104,748,050
JBrowse link
G Ces1d carboxylesterase 1D increases hydrolysis EXP CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A CTD PMID:8611161 NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions EXP valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A] CTD PMID:19854160 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
JBrowse link
G Dgat1 diacylglycerol O-acyltransferase 1 multiple interactions ISO DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A] CTD PMID:16214399 NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha decreases expression ISO Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein CTD PMID:17992261 NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein
Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
CTD PMID:11139385, PMID:18812576 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Shbg sex hormone binding globulin decreases expression ISO Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein CTD PMID:17992261 NCBI chr10:56,219,861...56,237,354
Ensembl chr10:56,219,858...56,223,245
JBrowse link
PD 168393 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] CTD PMID:25398788 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein] CTD PMID:25398788 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein CTD PMID:16413505 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein CTD PMID:16413505 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression
ISO PD168393 results in increased expression of and results in increased secretion of CCL2 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA] CTD PMID:21967610 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein CTD PMID:16413505 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions
increases expression
ISO acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; PD168393 results in increased expression of and results in increased secretion of CXCL10 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein] CTD PMID:21967610 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein CTD PMID:16413505 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Egfr epidermal growth factor receptor affects localization
multiple interactions
decreases phosphorylation
ISO
EXP
PD168393 affects the localization of EGFR protein; PD168393 affects the localization of EGFR protein modified form
PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]
PD168393 results in decreased phosphorylation of EGFR protein
CTD PMID:16413505, PMID:21967610, PMID:23527233, PMID:25398788 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of JAK3 protein] CTD PMID:16778083 NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK1 protein]; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein]
PD168393 results in decreased phosphorylation of MAPK1 protein
CTD PMID:16413505, PMID:16778083, PMID:23527233 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK3 protein]; PD168393 inhibits the reaction [resveratrol results in increased phosphorylation of MAPK3 protein]
PD168393 results in decreased phosphorylation of MAPK3 protein
CTD PMID:16413505, PMID:16778083, PMID:23527233 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK8 protein] CTD PMID:16778083 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased expression of MMP3 mRNA] CTD PMID:29535049 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA] CTD PMID:25398788 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP PD168393 inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein] CTD PMID:22031849 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein] CTD PMID:21967610 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]] CTD PMID:25398788 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein CTD PMID:16413505 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
pepstatin A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide] CTD PMID:17699715 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] CTD PMID:16850161 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions EXP pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased cleavage of BID protein] CTD PMID:22669516, PMID:28378122 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Casp3 caspase 3 multiple interactions EXP
ISO
pepstatin affects the reaction [thallium nitrate results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased activity of CASP3 protein]
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein modified form]
CTD PMID:22669516, PMID:26853465, PMID:28378122, PMID:31226464 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions EXP pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] CTD PMID:28378122 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein]
pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein modified form]
CTD PMID:28378122, PMID:31226464 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ctsb cathepsin B multiple interactions ISO [aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSB protein CTD PMID:32186374 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Ctsd cathepsin D multiple interactions
decreases activity
ISO
EXP
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSD protein; pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form]
pepstatin results in decreased activity of CTSD protein
CTD PMID:6497855, PMID:11423908, PMID:16850161, PMID:32186374 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Faslg Fas ligand multiple interactions EXP pepstatin inhibits the reaction [manganese chloride results in increased expression of FASLG protein] CTD PMID:28378122 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Hmga1 high mobility group AT-hook 1 multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of HMGA1 mRNA] CTD PMID:20660070 NCBI chr20:7,132,501...7,140,155
Ensembl chr20:7,136,007...7,138,980
JBrowse link
G Inhba inhibin subunit beta A multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA] CTD PMID:20660070 NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 multiple interactions ISO [aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of LAMP2 protein CTD PMID:32186374 NCBI chr  X:124,722,628...124,766,079
Ensembl chr  X:124,722,628...124,766,044
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO pepstatin promotes the reaction [BO-1051 results in increased expression of MAP1LC3B protein modified form] CTD PMID:21184746 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] CTD PMID:16850161 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of SQSTM1 protein CTD PMID:32186374 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stc1 stanniocalcin 1 multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC1 mRNA] CTD PMID:20660070 NCBI chr15:50,891,137...50,901,791
Ensembl chr15:50,891,127...50,903,162
JBrowse link
G Tnfaip6 TNF alpha induced protein 6 multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFAIP6 mRNA] CTD PMID:20660070 NCBI chr 3:37,545,238...37,564,704
Ensembl chr 3:37,545,238...37,564,699
JBrowse link
G Tomm20 translocase of outer mitochondrial membrane 20 multiple interactions ISO pepstatin inhibits the reaction [Doxorubicin results in decreased expression of TOMM20 protein] CTD PMID:31226464 NCBI chr19:59,863,421...59,873,411
Ensembl chr19:59,863,421...59,873,411
JBrowse link
PHA-665752 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of AKT1 protein] CTD PMID:22040890, PMID:25002221 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of BCL2L1 protein CTD PMID:20661229 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein
Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein]
CTD PMID:20661229 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in decreased expression of CAT protein] CTD PMID:22040890 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Egfr epidermal growth factor receptor decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]
CTD PMID:21266357 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] CTD PMID:20661229, PMID:21812414 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases activity
increases mutagenesis
decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased activity of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of and results in decreased activity of MET protein; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]
CTD PMID:20661229, PMID:21106725, PMID:21266357, PMID:21812414, PMID:25002221 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
CTD PMID:21266357 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
increases response to substance
increases expression
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA; Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein
CTD PMID:21266357 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of XIAP protein CTD PMID:20661229 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
phenylacetylglycine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine] CTD PMID:24709313 NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
JBrowse link
salicyluric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin multiple interactions ISO ALB protein binds to and affects the transport of salicylurate CTD PMID:8831264 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
salubrinal term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of FN1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; salubrinal inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein] CTD PMID:25398788 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein] CTD PMID:25398788 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO salubrinal results in increased expression of ATF3 mRNA CTD PMID:23690448 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
ISO
EXP
[salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein; salubrinal inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of ATF4 protein]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF4 protein]]; salubrinal promotes the reaction [Quercetin results in increased expression of ATF4 protein]
salubrinal promotes the reaction [Thapsigargin results in increased expression of ATF4 protein]; salubrinal promotes the reaction [Tunicamycin results in increased expression of ATF4 protein]
salubrinal promotes the reaction [Cisplatin results in increased expression of ATF4 protein]
salubrinal results in increased expression of ATF4 protein
CTD PMID:21616140, PMID:21809093, PMID:23690448, PMID:25611565, PMID:25950987, PMID:28844859, PMID:31022492 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 increases expression ISO salubrinal results in increased expression of ATF6 mRNA CTD PMID:23958496 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO
EXP
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased expression of BAX protein]]; salubrinal promotes the reaction [Cisplatin results in increased expression of BAX protein]
salubrinal inhibits the reaction [cadmium acetate results in increased expression of BAX protein]
CTD PMID:21616140, PMID:30605698 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO
EXP
salubrinal inhibits the reaction [alpha-Tocopherol analog results in decreased expression of BCL2 protein]; salubrinal inhibits the reaction [Quercetin results in decreased expression of BCL2 protein]
salubrinal inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein]
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]]; salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]
CTD PMID:20686688, PMID:21616140, PMID:25611565, PMID:30605698 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Becn1 beclin 1 multiple interactions ISO salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased expression of BECN1 protein] CTD PMID:20929985 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Calr calreticulin multiple interactions ISO [salubrinal results in decreased activity of [PPP1CC protein binds to PPP1R15A protein]] which affects the localization of CALR protein CTD PMID:17187072 NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
JBrowse link
G Casp12 caspase 12 multiple interactions ISO
EXP
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP12 protein]]; salubrinal inhibits the reaction [decamethrin results in increased expression of CASP12 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of CASP12 mRNA]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP12 protein]
salubrinal inhibits the reaction [arsenite results in increased activity of CASP12 protein]; salubrinal inhibits the reaction [Rotenone results in increased cleavage of CASP12 protein]
CTD PMID:18226606, PMID:21616140, PMID:25428620, PMID:26446018, PMID:31841155 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp3 caspase 3 multiple interactions ISO
EXP
salubrinal inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; salubrinal inhibits the reaction [MAP3K5 protein results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Paraquat results in increased activity of CASP3 protein]
salubrinal inhibits the reaction [Rotenone results in increased expression of CASP3 mRNA]; salubrinal inhibits the reaction [Tetrachlorodibenzodioxin results in increased cleavage of CASP3 protein]
salubrinal inhibits the reaction [decamethrin results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [decamethrin results in increased cleavage of and results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of CASP3 mRNA]; salubrinal promotes the reaction [Cisplatin results in increased activity of CASP3 protein]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]
CTD PMID:19735704, PMID:20929985, PMID:21616140, PMID:21809093, PMID:24932542, PMID:25428620, PMID:26446018, PMID:28986289, PMID:30247739, PMID:31841155 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions ISO Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein] CTD PMID:21616140 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA] CTD PMID:23958496 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA] CTD PMID:23958496 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in decreased expression of CDH1 protein] CTD PMID:22155090 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA] CTD PMID:23690541 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions EXP salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA] CTD PMID:23690541 NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO salubrinal inhibits the reaction [MAP3K5 protein affects the localization of CYCS protein]; salubrinal inhibits the reaction [Paraquat affects the localization of CYCS protein] CTD PMID:20929985 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
decreases expression
increases expression
ISO
EXP
EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; salubrinal inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Cadmium Chloride results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Quercetin results in increased expression of DDIT3 protein]
salubrinal results in decreased expression of DDIT3 protein
salubrinal inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Thapsigargin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Tunicamycin results in increased expression of DDIT3 protein]
salubrinal results in increased expression of DDIT3 mRNA
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased expression of DDIT3 protein]]; salubrinal inhibits the reaction [alpha-naphthoflavone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Cisplatin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Cyclosporine results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein]
CTD PMID:18305250, PMID:19735704, PMID:20686688, PMID:21616140, PMID:21809093, PMID:23690448, PMID:23958496, PMID:24932542, PMID:25428620, PMID:25611565, PMID:25950987, PMID:26446018, PMID:28844859, PMID:28986289, PMID:29380555, PMID:30508555, PMID:30605698 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Edem1 ER degradation enhancing alpha-mannosidase like protein 1 multiple interactions ISO salubrinal inhibits the reaction [Paraquat results in increased expression of EDEM1 protein] CTD PMID:19735704 NCBI chr 4:140,886,644...140,918,654
Ensembl chr 4:140,886,545...140,915,779
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions
increases expression
increases phosphorylation
affects phosphorylation
ISO
EXP
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of EIF2A protein]; salubrinal inhibits the reaction [EIF2A protein results in decreased susceptibility to nonivamide]
salubrinal results in increased expression of EIF2A protein modified form
salubrinal results in increased phosphorylation of EIF2A protein
salubrinal affects the phosphorylation of EIF2A protein
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased phosphorylation of EIF2A protein]]; salubrinal promotes the reaction [Cisplatin results in increased phosphorylation of EIF2A protein]
CTD PMID:17332266, PMID:17418795, PMID:18305250, PMID:18684481, PMID:20071420, PMID:20686688, PMID:20929985, PMID:21616140, PMID:23690541, PMID:23892647, PMID:27613715 NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases expression
increases phosphorylation
multiple interactions
ISO
EXP
salubrinal results in increased expression of EIF2S1 protein modified form
salubrinal results in increased phosphorylation of EIF2S1 protein
salubrinal inhibits the reaction [Rotenone results in decreased phosphorylation of EIF2S1 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK1 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK3 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK8 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK9 protein; salubrinal inhibits the reaction [cadmium acetate results in increased expression of EIF2S1 protein modified form]; salubrinal inhibits the reaction [Rotenone results in decreased phosphorylation of EIF2S1 protein]; salubrinal inhibits the reaction [Thapsigargin results in increased expression of EIF2S1 mRNA]; salubrinal inhibits the reaction [Tunicamycin results in increased expression of EIF2S1 mRNA]; salubrinal promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of EIF2S1 protein]
[salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein; [salubrinal results in decreased activity of EIF2S1 protein] which results in decreased susceptibility to decamethrin; EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased phosphorylation of EIF2S1 protein]]; salubrinal promotes the reaction [Cadmium Chloride results in increased phosphorylation of EIF2S1 protein]; salubrinal promotes the reaction [Paraquat results in increased expression of EIF2S1 protein modified form]; salubrinal promotes the reaction [Quercetin results in increased phosphorylation of EIF2S1 protein]; salubrinal results in increased phosphorylation of and results in decreased activity of EIF2S1 protein
CTD PMID:21147958, PMID:21555338, PMID:21809093, PMID:23690448, PMID:24932542, PMID:25170120, PMID:25428620, PMID:25611565, PMID:25950987, PMID:26446018, PMID:28844859, PMID:28986289, PMID:29380555, PMID:30605698, PMID:31022492 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Epo erythropoietin multiple interactions ISO [salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein; [salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein CTD PMID:23690448 NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
JBrowse link
G Fn1 fibronectin 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein results in increased expression of FN1 protein] CTD PMID:25398788 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP salubrinal inhibits the reaction [Rotenone results in decreased activity of GSR protein] CTD PMID:26446018 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO salubrinal promotes the reaction [Cisplatin results in increased expression of HAVCR1 mRNA] CTD PMID:21616140 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hgf hepatocyte growth factor multiple interactions EXP salubrinal inhibits the reaction [Thapsigargin results in decreased expression of HGF mRNA]; salubrinal inhibits the reaction [Thapsigargin results in decreased expression of HGF protein]; salubrinal inhibits the reaction [Tunicamycin results in decreased expression of HGF mRNA]; salubrinal inhibits the reaction [Tunicamycin results in decreased expression of HGF protein] CTD PMID:28844859 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
ISO
EXP
EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]
salubrinal inhibits the reaction [Rotenone results in increased expression of HSPA5 protein]
salubrinal results in increased expression of HSPA5 protein
salubrinal inhibits the reaction [Rotenone results in increased expression of HSPA5 protein]; salubrinal inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; salubrinal promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of HSPA5 protein]
CTD PMID:19735704, PMID:24932542, PMID:25428620, PMID:26446018, PMID:28844859, PMID:28986289, PMID:31022492 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 affects response to substance
multiple interactions
ISO salubrinal affects the susceptibility to MAP3K5 protein
salubrinal affects the susceptibility to [Paraquat co-treated with MAP3K5 protein]; salubrinal inhibits the reaction [MAP3K5 protein affects the localization of CYCS protein]; salubrinal inhibits the reaction [MAP3K5 protein results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Paraquat results in increased phosphorylation of and results in increased activity of MAP3K5 protein]; salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased expression of BECN1 protein]
CTD PMID:19735704, PMID:20929985 NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP
salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK1 protein
CTD PMID:21147958, PMID:22155090 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO salubrinal inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK14 protein] CTD PMID:21809093 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP
salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK3 protein
CTD PMID:21147958, PMID:22155090 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP
ISO
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK8 protein
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of MAPK8 protein]; salubrinal inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein]
CTD PMID:20686688, PMID:21147958, PMID:21809093 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO
EXP
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of MAPK9 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK9 protein
CTD PMID:20686688, PMID:21147958 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Myh3 myosin heavy chain 3 decreases expression ISO salubrinal results in decreased expression of MYH3 protein CTD PMID:29380555 NCBI chr10:53,621,375...53,645,194
Ensembl chr10:53,621,375...53,645,194
JBrowse link
G Myod1 myogenic differentiation 1 decreases expression ISO salubrinal results in decreased expression of MYOD1 protein CTD PMID:29380555 NCBI chr 1:102,396,538...102,399,248
Ensembl chr 1:102,396,538...102,399,248
JBrowse link
G Myog myogenin decreases expression ISO salubrinal results in decreased expression of MYOG protein CTD PMID:29380555 NCBI chr13:51,126,459...51,129,048
Ensembl chr13:51,126,459...51,129,048
JBrowse link
G Ngf nerve growth factor multiple interactions ISO salubrinal inhibits the reaction [decamethrin results in decreased expression of NGF protein] CTD PMID:31841155 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
ISO Acetylcysteine inhibits the reaction [salubrinal results in increased expression of [Cisplatin results in increased expression of NOX4 protein]] CTD PMID:21616140 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO salubrinal inhibits the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein]; salubrinal inhibits the reaction [Cyclosporine results in increased cleavage of PARP1 protein] CTD PMID:21809093, PMID:22155090 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Ppp1cc protein phosphatase 1 catalytic subunit gamma multiple interactions ISO [salubrinal results in decreased activity of [PPP1CC protein binds to PPP1R15A protein]] which affects the localization of CALR protein CTD PMID:17187072 NCBI chr12:39,864,302...39,882,030
Ensembl chr12:39,864,295...39,882,030
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A multiple interactions
increases expression
ISO [salubrinal results in decreased activity of [PPP1CC protein binds to PPP1R15A protein]] which affects the localization of CALR protein
salubrinal results in increased expression of PPP1R15A protein
CTD PMID:17187072, PMID:23690448 NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
JBrowse link
G Slc38a2 solute carrier family 38, member 2 multiple interactions ISO salubrinal promotes the reaction [arsenic trioxide results in increased expression of SLC38A2 mRNA] CTD PMID:23892647 NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
JBrowse link
G Smad2 SMAD family member 2 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein] CTD PMID:22155090 NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased degradation of SQSTM1 protein] CTD PMID:20929985 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA] CTD PMID:25398788 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO salubrinal inhibits the reaction [Quercetin results in decreased phosphorylation of STAT3 protein] CTD PMID:25611565 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein] CTD PMID:25398788 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Th tyrosine hydroxylase multiple interactions EXP salubrinal inhibits the reaction [Rotenone results in decreased expression of TH protein] CTD PMID:26446018 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in decreased expression of TJP1 protein] CTD PMID:22155090 NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
JBrowse link
G Trib3 tribbles pseudokinase 3 multiple interactions ISO salubrinal promotes the reaction [arsenic trioxide results in increased expression of TRIB3 mRNA] CTD PMID:23892647 NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression
multiple interactions
EXP salubrinal results in increased expression of VEGFA mRNA
salubrinal promotes the reaction [Thapsigargin results in increased expression of VEGFA mRNA]
CTD PMID:28844859 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
sivelestat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Elane elastase, neutrophil expressed decreases activity ISO sivelestat results in decreased activity of ELANE protein CTD PMID:19088179 NCBI chr 7:12,638,320...12,640,168
Ensembl chr 7:12,638,322...12,640,232
JBrowse link
SR 144528 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein] CTD PMID:12834810 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of ATF4 mRNA] CTD PMID:31054322 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of ATF6 mRNA] CTD PMID:31054322 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Casp3 caspase 3 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased activity of CASP3 protein] CTD PMID:16818634, PMID:16818650 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 protein]] CTD PMID:10218491 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased expression of CDK1 protein] CTD PMID:16818634 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions ISO SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] CTD PMID:11891798 NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
JBrowse link
G Cnr2 cannabinoid receptor 2 affects binding
multiple interactions
ISO
EXP
SR 144528 binds to CNR2 protein
[SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog; [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to Win 55212-2; SR 144528 binds to and results in decreased activity of CNR2 protein; SR 144528 inhibits the reaction [[3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo(c)chromen-6-one binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [[AM 1241 binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [CNR2 protein affects the susceptibility to Dronabinol]
[SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; SR 144528 binds to and results in decreased activity of CNR2 protein; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 protein]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CXCL8 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CXCL8 protein]]
CTD PMID:10218491, PMID:10617657, PMID:10688601, PMID:12509806, PMID:15115777, PMID:17558434, PMID:17558435, PMID:17572696, PMID:18247131, PMID:18664590, PMID:21702498, PMID:21871882 NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of DDIT3 mRNA] CTD PMID:31054322 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Gata3 GATA binding protein 3 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of GATA3 mRNA] CTD PMID:14741435 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of HSPA5 mRNA] CTD PMID:31054322 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Ifng interferon gamma multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IFNG mRNA]; SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IFNG protein] CTD PMID:12446015 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il10 interleukin 10 multiple interactions ISO SR 144528 inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]] CTD PMID:15821753 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il12b interleukin 12B multiple interactions ISO SR 144528 inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]] CTD PMID:15821753 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; SR 144528 inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]] CTD PMID:15748152 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IL2 mRNA] CTD PMID:12446015 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il4 interleukin 4 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL4 mRNA]; SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL4 protein] CTD PMID:12446015 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il5 interleukin 5 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL5 mRNA] CTD PMID:12446015 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions ISO SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of IRF1 protein]] CTD PMID:28624443 NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK1 protein] CTD PMID:12834810 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK3 protein] CTD PMID:12834810 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK8 protein] CTD PMID:24184660 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK9 protein] CTD PMID:24184660 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] CTD PMID:15748152 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of NUPR1 mRNA] CTD PMID:16818650 NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased localization of RAF1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased localization of RAF1 protein] CTD PMID:12834810 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of TGFB1 protein] CTD PMID:11779138 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of IRF1 protein]]; SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] CTD PMID:28624443 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] CTD PMID:28624443 NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO SR 144528 inhibits the reaction [Win 55212-2 results in decreased expression of and results in decreased secretion of VEGFA protein] CTD PMID:15313899 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of XBP1 mRNA alternative form] CTD PMID:31054322 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
stearoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO stearoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO stearoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO stearoyl-coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
succinyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acot4 acyl-CoA thioesterase 4 affects hydrolysis ISO ACOT4 protein affects the hydrolysis of succinyl-coenzyme A CTD PMID:16141203 NCBI chr 6:107,517,668...107,522,952
Ensembl chr 6:107,517,668...107,522,952
JBrowse link
sulfoglycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc10a1 solute carrier family 10 member 1 increases uptake ISO SLC10A1 protein results in increased uptake of sulfolithocholylglycine CTD PMID:29024779 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
suramin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Calca calcitonin-related polypeptide alpha multiple interactions EXP Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] CTD PMID:12044622 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Casp1 caspase 1 multiple interactions EXP Suramin inhibits the reaction [Glucose results in increased activity of CASP1 protein] CTD PMID:21832250 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Casp3 caspase 3 multiple interactions ISO Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]; Suramin inhibits the reaction [Clodronic Acid results in increased expression of CASP3] CTD PMID:19448140 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Chrna7 cholinergic receptor nicotinic alpha 7 subunit increases expression ISO Suramin results in increased expression of CHRNA7 protein CTD PMID:23516405 NCBI chr 1:123,897,341...124,039,263
Ensembl chr 1:123,899,657...124,039,196
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of CREB1 protein] CTD PMID:18612546 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity ISO Suramin results in decreased activity of CYP1A2 protein CTD PMID:11124226 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO Suramin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] CTD PMID:22167199 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 decreases activity ISO Suramin results in decreased activity of CYP2C19 protein CTD PMID:11124226 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions EXP Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] CTD PMID:9710602 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Fgf2 fibroblast growth factor 2 increases expression ISO Suramin results in increased expression of FGF2 CTD PMID:8394679 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Fgf5 fibroblast growth factor 5 increases expression ISO Suramin results in increased expression of FGF5 CTD PMID:8394679 NCBI chr14:12,974,921...12,996,046
Ensembl chr14:12,974,921...12,995,584
JBrowse link
G Fgf7 fibroblast growth factor 7 affects localization
multiple interactions
ISO Suramin affects the localization of FGF7 protein
Suramin inhibits the reaction [FGF7 protein binds to FGFR2 protein]
CTD PMID:15733146 NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 multiple interactions ISO Suramin inhibits the reaction [FGF7 protein binds to FGFR2 protein] CTD PMID:15733146 NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
JBrowse link
G Fmr1 FMRP translational regulator 1 multiple interactions ISO Suramin inhibits the reaction [Poly I-C results in decreased expression of FMR1 protein] CTD PMID:23516405 NCBI chr  X:154,684,924...154,722,369
Ensembl chr  X:154,684,935...154,722,314
JBrowse link
G Hpgds hematopoietic prostaglandin D synthase decreases activity ISO Suramin results in decreased activity of HPGDS protein CTD PMID:25603235 NCBI chr 4:95,945,356...95,970,666
Ensembl chr 4:95,946,025...95,970,666
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases activity
ISO Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of IL10 protein]
Suramin results in decreased activity of IL10 protein
CTD PMID:15914193 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il12b interleukin 12B increases expression ISO Suramin results in increased expression of IL12B protein CTD PMID:15914193 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il6 interleukin 6 multiple interactions ISO Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Silicon Dioxide analog results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]
Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
CTD PMID:24793913, PMID:24849676 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Lmna lamin A/C multiple interactions ISO Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein] CTD PMID:23217256 NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK1 protein]
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]
Suramin inhibits the reaction [2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]
CTD PMID:8758915, PMID:9710602, PMID:14674888, PMID:15930183, PMID:18612546, PMID:23516405 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK3 protein]
Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein]
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CTD PMID:9710602, PMID:14674888, PMID:15930183, PMID:18612546, PMID:23516405 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G P2rx3 purinergic receptor P2X 3 multiple interactions EXP Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein] CTD PMID:23666265 NCBI chr 3:72,403,992...72,447,801
Ensembl chr 3:72,403,993...72,447,801
JBrowse link
G P2rx7 purinergic receptor P2X 7 multiple interactions ISO Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RX7 protein] CTD PMID:23516405 NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
JBrowse link
G P2ry2 purinergic receptor P2Y2 decreases activity
multiple interactions
EXP
ISO
Suramin results in decreased activity of P2RY2 protein
Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RY2 protein]
CTD PMID:15654852, PMID:23516405 NCBI chr 1:166,031,228...166,045,423
Ensembl chr 1:166,031,272...166,037,424
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO JTE 013 promotes the reaction [Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin promotes the reaction [JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]] CTD PMID:18612546 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
EXP
ISO
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein]
Suramin results in increased expression of SHC1 mRNA; Suramin results in increased expression of SHC1 protein
CTD PMID:9710602, PMID:21778425 NCBI chr 2:188,745,503...188,757,066
Ensembl chr 2:188,745,503...188,757,066
JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein]; Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
[Suramin results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol
CTD PMID:18482975, PMID:23217256, PMID:24252177 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Tacr1 tachykinin receptor 1 multiple interactions EXP Suramin inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] CTD PMID:23666265 NCBI chr 4:113,247,236...113,416,139
Ensembl chr 4:113,247,795...113,414,504
JBrowse link
G Tnf tumor necrosis factor increases expression ISO Suramin results in increased expression of TNF protein CTD PMID:15914193 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] CTD PMID:18482975 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Vdr vitamin D receptor multiple interactions ISO Suramin inhibits the reaction [Estradiol results in increased expression of VDR protein] CTD PMID:15930183 NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
JBrowse link
teriflunomide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO A 771726 results in decreased phosphorylation of AKT1 protein CTD PMID:19174558 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO A 771726 results in decreased expression of BCL2L1 mRNA CTD PMID:29427785 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO A 771726 results in increased expression of BNIP3 mRNA CTD PMID:29427785 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G Ccna2 cyclin A2 increases expression ISO A 771726 results in increased expression of CCNA2 protein CTD PMID:12181422 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO A 771726 results in decreased expression of CCND2 protein CTD PMID:19174558 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccne1 cyclin E1 decreases expression
increases expression
ISO A 771726 results in decreased expression of CCNE1 protein
A 771726 results in increased expression of CCNE1 protein
CTD PMID:12181422, PMID:19174558 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cdc25a cell division cycle 25A decreases expression ISO A 771726 results in decreased expression of CDC25A protein CTD PMID:19174558 NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO A 771726 results in increased expression of CDKN1A protein CTD PMID:12181422 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Chdh choline dehydrogenase decreases expression ISO A 771726 results in decreased expression of CHDH mRNA CTD PMID:29427785 NCBI chr16:6,078,083...6,109,386
Ensembl chr16:6,078,122...6,109,382
JBrowse link
G Cxcr1 C-X-C motif chemokine receptor 1 decreases expression ISO A 771726 results in decreased expression of CXCR1 mRNA CTD PMID:10076546 NCBI chr 9:81,466,430...81,469,299
Ensembl chr 9:81,466,332...81,469,274
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 decreases expression ISO A 771726 results in decreased expression of CYP24A1 mRNA CTD PMID:29427785 NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases activity
increases expression
ISO teriflunomide results in increased activity of CYP2B6 protein
teriflunomide results in increased expression of CYP2B6 mRNA
CTD PMID:30364229 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Ddx28 DEAD-box helicase 28 decreases expression ISO A 771726 results in decreased expression of DDX28 mRNA CTD PMID:29427785 NCBI chr19:37,988,423...37,990,353
Ensembl chr19:37,988,423...37,990,353
JBrowse link
G Dhodh dihydroorotate dehydrogenase (quinone) multiple interactions
decreases activity
decreases expression
ISO
EXP
A 771726 inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]
A 771726 results in decreased activity of DHODH protein
A 771726 results in decreased expression of DHODH mRNA
A 771726 inhibits the reaction [DHODH protein results in increased metabolism of 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone]; A 771726 inhibits the reaction [DHODH protein results in increased metabolism of 4,5-dihydroorotic acid]; A 771726 inhibits the reaction [DHODH protein results in increased metabolism of Ubiquinone]; A 771726 inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; A 771726 inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]
CTD PMID:9776318, PMID:9802339, PMID:11248707, PMID:29427785 NCBI chr19:42,066,103...42,087,906
Ensembl chr19:42,066,351...42,082,012
JBrowse link
G Egf epidermal growth factor multiple interactions ISO teriflunomide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] CTD PMID:30364229 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO teriflunomide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] CTD PMID:30364229 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 decreases phosphorylation ISO A 771726 results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:19174558 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Fars2 phenylalanyl-tRNA synthetase 2, mitochondrial decreases expression ISO A 771726 results in decreased expression of FARS2 mRNA CTD PMID:29427785 NCBI chr17:29,006,981...29,438,906
Ensembl chr17:29,006,988...29,438,668
JBrowse link
G Fasn fatty acid synthase decreases expression
multiple interactions
ISO teriflunomide results in decreased expression of FASN mRNA
[Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA
CTD PMID:30364229 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 increases expression
multiple interactions
ISO teriflunomide results in increased expression of G6PC mRNA
Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC mRNA]
CTD PMID:30364229 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like decreases expression ISO A 771726 results in decreased expression of HSPA1L mRNA CTD PMID:29427785 NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
JBrowse link
G Il10ra interleukin 10 receptor subunit alpha increases expression ISO A 771726 results in increased expression of IL10RA mRNA; A 771726 results in increased expression of IL10RA protein CTD PMID:10076546 NCBI chr 8:49,558,062...49,573,891
Ensembl chr 8:49,560,035...49,573,742
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase multiple interactions ISO A 771726 inhibits the reaction [TNF protein results in increased activity of LCK protein] CTD PMID:9973483 NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO A 771726 inhibits the reaction [TNF protein results in increased activity of MAP2K1 protein] CTD PMID:9973483 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Mtfr2 mitochondrial fission regulator 2 decreases expression ISO A 771726 results in decreased expression of MTFR2 mRNA CTD PMID:29427785 NCBI chr 1:15,834,779...15,850,424
Ensembl chr 1:15,782,477...15,860,624
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO A 771726 inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; A 771726 inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]; Ceramides inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Hydrogen Peroxide inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Lipopolysaccharides inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Okadaic Acid inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Tetradecanoylphorbol Acetate inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:9973483 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO A 771726 inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein] CTD PMID:9973483 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression
affects localization
ISO teriflunomide results in increased expression of NR1I3 mRNA
teriflunomide affects the localization of NR1I3 protein mutant form
CTD PMID:30364229 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions
increases activity
ISO Mifepristone inhibits the reaction [teriflunomide results in increased activity of NR3C1 protein] CTD PMID:30364229 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Oat ornithine aminotransferase increases expression ISO A 771726 results in increased expression of OAT mRNA CTD PMID:29427785 NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 increases expression
multiple interactions
ISO teriflunomide results in increased expression of PCK1 mRNA
Colforsin inhibits the reaction [teriflunomide results in increased expression of PCK1 mRNA]
CTD PMID:30364229 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases expression ISO A 771726 results in decreased expression of RB1 protein CTD PMID:19174558 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO A 771726 inhibits the reaction [TNF protein affects the localization of RELA protein]; A 771726 inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; A 771726 inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]; Ceramides inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Hydrogen Peroxide inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Lipopolysaccharides inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Okadaic Acid inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]]; Tetradecanoylphorbol Acetate inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:9973483 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO A 771726 results in decreased phosphorylation of RPS6KB1 protein CTD PMID:19174558 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Slc25a25 solute carrier family 25 member 25 increases expression ISO A 771726 results in increased expression of SLC25A25 mRNA CTD PMID:29427785 NCBI chr 3:11,442,396...11,476,186
Ensembl chr 3:11,442,397...11,452,529
JBrowse link
G Tfb1m transcription factor B1, mitochondrial decreases expression ISO A 771726 results in decreased expression of TFB1M mRNA CTD PMID:29427785 NCBI chr 1:44,433,116...44,474,674
Ensembl chr 1:44,433,116...44,474,674
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP A 771726 inhibits the reaction [Carbon Tetrachloride results in increased secretion of TGFB1 protein] CTD PMID:15586409 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
A 771726 inhibits the reaction [TNF protein affects the localization of RELA protein]; A 771726 inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; A 771726 inhibits the reaction [TNF protein results in increased activity of LCK protein]; A 771726 inhibits the reaction [TNF protein results in increased activity of MAP2K1 protein]; A 771726 inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; A 771726 inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]
A 771726 inhibits the reaction [Carbon Tetrachloride results in increased secretion of TNF protein]
CTD PMID:9973483, PMID:15586409 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 increases expression ISO A 771726 results in increased expression of TP53 mRNA; A 771726 results in increased expression of TP53 protein CTD PMID:10076546 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tuba1a tubulin, alpha 1A affects expression ISO teriflunomide affects the expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:140,637,287...140,640,953
Ensembl chr 7:140,637,287...140,640,953
JBrowse link
tranilast term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor increases response to substance
increases expression
multiple interactions
ISO AHR protein results in increased susceptibility to tranilast
tranilast results in increased expression of AHR mRNA
AHR protein promotes the reaction [tranilast results in increased expression of AHR mRNA]; AHR protein promotes the reaction [tranilast results in increased expression of CYP1A1 mRNA]; tranilast promotes the reaction [AHR protein binds to CYP1A1 promoter]
CTD PMID:25826687 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO tranilast results in decreased expression of CXCR4 mRNA CTD PMID:25826687 NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression
ISO AHR protein promotes the reaction [tranilast results in increased expression of CYP1A1 mRNA]; tranilast promotes the reaction [AHR protein binds to CYP1A1 promoter] CTD PMID:25826687 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 affects expression ISO tranilast affects the expression of CYP1B1 mRNA CTD PMID:25826687 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO tranilast inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] CTD PMID:23769903 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
tyrphostin B42 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Jak2 Janus kinase 2 decreases expression EXP Turphostin B42 decreased expression of Jak2 mRNA in myofibroblasts RGD PMID:26385087 RGD:18337263 NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
JBrowse link
WIN 18446 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases activity EXP
ISO
N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine results in decreased activity of ALDH1A2 protein CTD PMID:12547725, PMID:30958995 NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine inhibits the reaction [Vitamin A results in increased expression of HOXA1 mRNA] CTD PMID:23696197 NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
JBrowse link
ximelagatran term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G F2 coagulation factor II decreases cleavage
multiple interactions
ISO ximelagatran results in decreased cleavage of F2 protein
ximelagatran binds to and results in decreased activity of F2 protein
CTD PMID:15155122, PMID:16084352, PMID:16194202, PMID:17314111 NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    chemical entity 19816
      atom 19814
        nonmetal atom 19690
          nitrogen atom 18565
            nitrogen molecular entity 18565
              organonitrogen compound 18338
                carboxamide 17158
                  secondary carboxamide 268
                    (-)-Jasmonoyl-L-isoleucine 0
                    (1R)-Hydroxy-(2R)-N-acetyl-L-cysteinyl-1,2-dihydronaphthalene 0
                    (1R)-N-Acetyl-L-cysteinyl-(2R)-hydroxy-1,2-dihydronaphthalene 0
                    (1S)-Hydroxy-(2S)-N-acetyl-L-cysteinyl-1,2-dihydronaphthalene 0
                    (2E,24R)-24-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-2-methylpentacos-2-enamide 0
                    (2R)-N-[(2S)-3,3-dimethyl-1-oxo-1-[[(1R)-1-phenylethyl]amino]butan-2-yl]-N'-hydroxy-2-[3-(3-methyl-4-phenylphenyl)propyl]butanediamide 0
                    (2S)-2-[[(2-chlorophenyl)-oxomethyl]amino]-3-methylbutanoic acid (3-cyano-4-imino-2-oxopentyl) ester 0
                    (2S)-2-[[(2-chlorophenyl)-oxomethyl]amino]-3-methylbutanoic acid (6-nitro-4H-1,3-benzodioxin-8-yl)methyl ester 0
                    (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-phenylacetic acid cyclopentyl ester 0
                    (2S)-2-[[(2S)-2-[(2S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                    (2S)-2-[[(2S)-2-[(2S,3R)-2-[(2-amino-3-mercaptopropyl)amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                    (2S)-2-[[2-[(2S,3S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                    (2S)-2-[[[5-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]propanoic acid tert-butyl ester 0
                    (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                    (2S)-2-acetamido-3-(1H-indol-3-yl)propanamide 0
                    (2S)-3-methyl-2-[[(3-methylphenyl)-oxomethyl]amino]butanoic acid (4-oxo-2-pyrimido[2,1-b][1,3]benzothiazolyl)methyl ester 0
                    (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                    (2S,3S,4R)-4-cyclopropyl-2-ethoxy-3-(3-hydroxypropyl)-N-prop-2-ynyl-3,4-dihydro-2H-pyran-6-carboxamide 0
                    (6R,7R)-7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 0
                    (R)-N-trans-feruloyloctopamine 0
                    (Z)-N-cyclopropyl-11-methyldodec-2-enamide 0
                    (Z)-N-cyclopropyldodec-2-enamide 0
                    1-amino-15-oxo-4,7,10-trioxa-14-azaoctadecan-18-oic acid 0
                    1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-N-[4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]-1,4-dihydroquinoline-3-carboxamide 0
                    2,2,2-trideuterio-N-[1,1,2,2-tetradeuterio-2-(5-hydroxy-1H-indol-3-yl)ethyl]acetamide 0
                    2,2,2-trifluoro-N-(2-methyl-8-quinolinyl)acetamide 0
                    2,2,2-trifluoro-N-(5-oxo-1-phenyl-4H-pyrazol-3-yl)acetamide 0
                    2,2,2-trifluoro-N-(8-hydroxyoctyl)acetamide + 0
                    2,2,2-trifluoro-N-[2-(1H-indol-3-yl)ethyl]acetamide 0
                    2,9-dideoxy-9-glutaramido-2,3-dehydo-N-acetylneuraminic acid 0
                    2-(1H-benzimidazol-2-yl)-N-(2-furanylmethyl)-3-[3-(trifluoromethyl)phenyl]-2-propenamide 0
                    2-(2,4-dioxo-1H-pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[2-[[3-(2-chlorophenyl)-1-oxoprop-2-enyl]amino]-4-thiazolyl]acetic acid ethyl ester 0
                    2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid 0
                    2-[[1-oxo-3-(4-pentylphenyl)prop-2-enyl]amino]benzoic acid 0
                    2-[[2-(3,4-dimethoxyanilino)-2-oxoethyl]thio]-3-pyridinecarboxylic acid propan-2-yl ester 0
                    2-[[2-cyano-3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]-4-phenyl-3-thiophenecarboxylic acid ethyl ester 0
                    2-[[3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid 0
                    2-[[3-(4-methoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid 0
                    2-[[oxo(thiophen-2-yl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester 0
                    2-\{[2-(2-chlorophenyl)-2-hydroxyethyl]amino\}-N-[(2-fluorophenyl)methyl]acetamide 0
                    2-chloro-N-(4-fluorophenyl)-3-phenyl-2-propenamide 0
                    2-chloro-N-[2-[2-[(5-chloro-3-methyl-1-phenyl-4-pyrazolyl)methylidene]hydrazinyl]-2-oxoethyl]benzamide 0
                    2-chloro-N-[2-[2-[(5-nitro-2-thiophenyl)methylidene]hydrazinyl]-2-oxoethyl]benzamide 0
                    2-cyano-3-(1,3-dimethyl-2-oxo-5-benzimidazolyl)-N-(4-methoxyphenyl)-2-propenamide 0
                    2-cyano-3-(4,5-dimethoxy-2-nitrophenyl)-N-(2-oxolanylmethyl)-2-propenamide 0
                    2-cyano-N-(2-methoxyphenyl)-3-[5-nitro-2-(1-pyrrolidinyl)phenyl]-2-propenamide 0
                    2-cyano-N-(3-methylphenyl)-3-[4-(methylthio)phenyl]-2-propenamide 0
                    2-cyano-N-(4-ethoxyphenyl)-3-[3-methyl-4-(1-pyrrolidinyl)phenyl]-2-propenamide 0
                    2-cyano-N-[3-(1-imidazolyl)propyl]-3-(4-nitrophenyl)-2-propenamide 0
                    2-cyano-N-cyclohexyl-3-[4-(methylthio)phenyl]-2-propenamide 0
                    2-methyl-N-(6-nitro-1,3-benzothiazol-2-yl)-3-phenyl-2-propenamide 0
                    3',4'-difluoro-N-\{4'-fluoro-6-[(3S)-pyrrolidin-3-yloxy][biphenyl]-3-yl\}-6-[(3S)-pyrrolidin-3-yloxy][biphenyl]-3-carboxamide 0
                    3-(1,3-benzodioxol-5-yl)-2-cyano-N-(4-hydroxyphenyl)-2-propenamide 0
                    3-(1,3-benzodioxol-5-yl)-N-(4-phenyl-2-thiazolyl)-2-propenamide 0
                    3-(1,3-benzodioxol-5-yl)-N-[2-(4-methylphenyl)-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]-2-propenamide 0
                    3-(1,3-benzodioxol-5-yl)-N-[2-[(4-chlorophenyl)methylthio]ethyl]-2-propenamide 0
                    3-(2,4-dimethylphenyl)-N-(thiophen-2-ylmethyl)-2-propenamide 0
                    3-(2-chloro-6-fluorophenyl)-N-pyridin-4-yl-2-propenamide 0
                    3-(2-chlorophenyl)-N-[4-(dimethylsulfamoyl)phenyl]-2-propenamide 0
                    3-(2-chlorophenyl)-N-pyridin-4-yl-2-propenamide 0
                    3-(2-nitrophenyl)-N-(3-pyridinyl)-2-propenamide 0
                    3-(3-anilino-3-oxoprop-1-enyl)-N-hydroxybenzamide 0
                    3-(4-chlorophenyl)-N-(3-methoxyphenyl)-2-propenamide 0
                    3-(4-fluorophenyl)-N-(6-methoxy-3-pyridinyl)-2-propenamide 0
                    3-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)-2-propenamide 0
                    3-(4-methoxyphenyl)-N-(11-oxo-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-2-yl)-2-propenamide 0
                    3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propenamide 0
                    3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide + 0
                    3-[3-[(2-bromo-4-chlorophenoxy)methyl]-4-methoxyphenyl]-N-[(1,3-dimethyl-4-pyrazolyl)methyl]-2-propenamide 0
                    3-amino-6-chloro-5-(dimethylamino)-N-(3-pyridinyl)-2-pyrazinecarboxamide 0
                    3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide 0
                    3-bromo-N-\{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl\}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide + 0
                    3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}-L-phenylalaninamide 0
                    3-methyl-2-[[oxo-(4-pentoxyphenyl)methyl]amino]butanoic acid 0
                    3-phenyl-N-(3-pyridinyl)-2-propenamide 0
                    3-phenyl-N-[2,2,2-trichloro-1-[[(8-quinolinylamino)-sulfanylidenemethyl]amino]ethyl]-2-propenamide 0
                    4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide 0
                    4-(2,6-difluorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide 0
                    4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide 0
                    4-[[(4-bromo-2-ethyl-3-pyrazolyl)-oxomethyl]amino]benzoic acid propan-2-yl ester 0
                    4-[[2-furanyl(oxo)methyl]amino]benzoic acid propan-2-yl ester 0
                    4-[[4-[2-cyano-3-(4-methoxyanilino)-3-oxoprop-1-enyl]-2-methoxyphenoxy]methyl]benzoic acid 0
                    4-chloro-N-[1-[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-3-methyl-1-oxobutan-2-yl]benzamide 0
                    4-chloro-N-[3-(3-methylanilino)-1-(5-nitro-2-furanyl)-3-oxoprop-1-en-2-yl]benzamide 0
                    4-hydroxyprotoasukamycin + 0
                    4-methylbenzenesulfonic acid [4-(3-amino-2-cyano-3-oxoprop-1-enyl)-2-methoxyphenyl] ester 0
                    5-(3-azidopropylamino)-5-oxopentanoic acid + 0
                    5-(4,6-dioxo-3-propan-2-yl-1-cyclohex-2-enylidene)-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-2H-isoxazole-3-carboxamide 0
                    5-[[3-(1,5-dimethyl-4-pyrazolyl)-1-oxoprop-2-enyl]amino]-3-methylthiophene-2,4-dicarboxylic acid O2-ethyl ester O4-propan-2-yl ester 0
                    ANA-12 0
                    Arachidonoyl dopamine 0
                    Asn-Ile 0
                    BMS 195614 0
                    Butoctamide hydrogen succinate 0
                    CDN1163 0
                    CX-5461 0
                    Capsi-amide 0
                    Cuscuta propenamide 1 0
                    Cuscuta propenamide 2 0
                    Cyanthoate 0
                    Cys-Ser 0
                    DEL-22379 0
                    EI-1511-3 0
                    Fagaramide 0
                    LGK974 7
                    LSM-14399 0
                    LSM-17442 0
                    LSM-4709 0
                    LSM-9991 0
                    LimKi 3 0
                    MI-63 0
                    MMP-9-IN-1 0
                    N(1),N(8)-bis(coumaroyl)spermidine 0
                    N(1),N(8)-bis(sinapoyl)-spermidine 0
                    N(1),N(8)-bis-(dihydrocaffeoyl)spermidine 0
                    N(2)-(3-hydroxy-3-methylhexanoyl)-L-glutamine 0
                    N(2)-[(2E)-3-methylhex-2-enoyl]-L-glutamine 0
                    N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-3,3-dimethoxyalaninamide 0
                    N(2)-[4-(indol-3-yl)butanoyl]-L-glutamine 0
                    N(3)-fumaramoyl-(S)-2,3-diaminopropanoic acid 0
                    N(3)-fumaroyl-(S)-2,3-diaminopropanoic acid 0
                    N(4)-acetyl-2'-deoxycytidine 0
                    N(4)-acetylcytidine 0
                    N(6)-trifluoroacetyl-L-lysine 0
                    N,N',N''-tris(3-pyridyl)benzene-1,3,5-tricarboxamide 0
                    N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                    N,O-diacylethanolamine + 0
                    N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                    N-(1-phenylethyl)acetamide + 0
                    N-(11-oxo-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-2-yl)-3-(3,4,5-trimethoxyphenyl)-2-propenamide 0
                    N-(2-anilino-2-oxoethyl)-2-methoxybenzamide 0
                    N-(2-hydroxydocosanoyl)eicosasphinganine 0
                    N-(2-hydroxyhexacosanoyl)phytosphingosine + 0
                    N-(3-anilino-3-oxo-1-phenylprop-1-en-2-yl)benzamide 0
                    N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide 0
                    N-(3-methoxyphenyl)-3-(4-nitrophenyl)-2-propenamide 0
                    N-(3-oxohexanoyl)homoserine lactone 0
                    N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                    N-(4-carboxy-4-oxobutanoyl)-L-ethylglycylglycine 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)-1-(N,N-dimethylglycyl)piperidine-4-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)-2-(4-methylpiperazin-1-yl)pyridine-4-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-carboxamide 0
                    N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-3-(4-fluorophenyl)-2-propenamide 0
                    N-(5-methyl-3-isoxazolyl)-3-(4-methylphenyl)-2-propenamide 0
                    N-(5-methyl-3-isoxazolyl)-3-phenyl-2-propenamide 0
                    N-([biphenyl]-2-yl)-3-cyclopentylpropanamide 0
                    N-(naphthyl)carboxamide + 1
                    N-(p-amylcinnamoyl)anthranilic acid 2
                    N-(saturated fatty acyl)ethanolamine + 6
                    N-(tert-butoxycarbonyl)-L-seryl-L-valyl-N-\{(2S,3E)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl\}-L-leucinamide 0
                    N-(trifluoroacetyl)glycine 0
                    N-Methylolacrylamide 6
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S)-1-(1H-benzimidazol-2-ylamino)-3-methyl-1-oxobutan-2-yl]-3,5-dimethoxybenzamide 0
                    N-[(2S)-1-(1H-benzimidazol-2-ylamino)-3-methyl-1-oxobutan-2-yl]-3-methylbenzamide 0
                    N-[(2S)-2-aminobutanoyl]glycine 0
                    N-[(2S)-3-cyclohexyl-1-oxo-1-(\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}amino)propan-2-yl]-1H-indole-2-carboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(4-chlorophenyl)methyl]-2-(2,4-dioxo-1H-pyrimidin-6-yl)acetamide 0
                    N-[(6-hydroxyindol-3-yl)acetyl]phenylalanine 0
                    N-[1-(2,5-dimethoxyphenyl)-3-[2-[(5-methyl-2-thiophenyl)methylidene]hydrazinyl]-3-oxoprop-1-en-2-yl]benzamide 0
                    N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                    N-[1-[(4-chlorophenyl)methyl]-4-pyrazolyl]-2-pyrazinecarboxamide 0
                    N-[2-(2-methoxyphenoxy)ethyl]-3-(4-methoxyphenyl)-2-propenamide 0
                    N-[2-(3,4-dihydroxyphenyl)ethyl]-9-octadecenamide 0
                    N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                    N-[2-[3-(dimethylamino)propylthio]phenyl]-3-phenyl-2-propenamide 0
                    N-[2-chloro-5-(trifluoromethyl)phenyl]-2-cyano-3-[3-methoxy-4-[2-oxo-2-[3-(trifluoromethyl)anilino]ethoxy]phenyl]-2-propenamide 0
                    N-[3-(4-\{[1-(5-chloro-2,4-dimethoxyanilino)-1-oxopropan-2-yl]sulfanyl\}anilino)-3-oxo-1-phenylprop-1-en-2-yl]benzamide 0
                    N-[3-(4-hydroxyanilino)-3-oxo-1-pyridin-4-ylprop-1-en-2-yl]benzamide 0
                    N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide 0
                    N-[3-(diethylsulfamoyl)phenyl]-3-(3-nitrophenyl)-2-propenamide 0
                    N-[3-[2-[(4-methoxyphenyl)methylidene]hydrazinyl]-1-[(4-methyl-2-pyrimidinyl)amino]-3-oxoprop-1-en-2-yl]benzamide 0
                    N-[3-[3-(dimethylamino)propylamino]-1-[5-(3-nitrophenyl)-2-furanyl]-3-oxoprop-1-en-2-yl]benzamide 0
                    N-[4-(4-morpholinylmethyl)phenyl]-3-phenyl-2-propenamide 0
                    N-[4-(indol-3-yl)butanoyl]-L-cysteine 0
                    N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N(2),N(2)-dimethylglycinamide 0
                    N-[5-[(2,6-dichlorophenyl)methylthio]-1,3,4-thiadiazol-2-yl]-5-methyl-2-pyrazinecarboxamide 0
                    N-[[4-oxo-4-(2-pyridinylamino)butan-2-ylidene]amino]-2-pyrazinecarboxamide 0
                    N-\{3-[(5-cyclopropyl-2-\{[3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]amino\}pyrimidin-4-yl)amino]propyl\}cyclobutanecarboxamide 0
                    N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide 0
                    N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide 0
                    N-acetylcadaverine 0
                    N-acetyldopamine 1
                    N-acyl-L-alanine + 3
                    N-acyl-O-(3-sn-phosphatidyl)-L-serine + 0
                    N-acyl-gamma-aminobutyric acid + 0
                    N-acylglycine + 21
                    N-benzoyl-D-arginine-4-nitroanilide 0
                    N-benzoyl-L-phenylalaninol + 2
                    N-benzylhexadecanamide 0
                    N-butyl-N(2)-(2-thienylacetyl)-L-alaninamide 0
                    N-butyl-N(2)-[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]-L-alaninamide 0
                    N-butyl-N(2)-[(R)-2-hydroxy-2-phenylacetyl]-L-alaninamide 0
                    N-caffeoylspermidine 0
                    N-decanoylglycine 0
                    N-feruloylserotonin 0
                    N-malonyltryptophan 0
                    N-oleoyldopamine 2
                    N-pyrazin-2-yl-N(2)-\{1-[2-(1H-pyrazol-1-yl)phenyl]ethyl\}glycinamide 0
                    N-trans-feruloyl-4'-O-methyldopamine 0
                    N1,N5,N10-Tricaffeoyl spermidine 0
                    O(3)-(2-L-lysino-2-oxoethyl)-O(1)-[4-(trifluoroacetamido)benzylcarbonyl]chloramphenicol 0
                    Oroidine 0
                    PA-16-0081C 0
                    PD 168393 19
                    PHA-533533 0
                    PHA-665752 12
                    Propanoylagmatine 0
                    RO4927350 0
                    SG85 0
                    SGC-CK2-1 0
                    SNIR3 dye 0
                    SR 144528 31
                    SU1498 0
                    Sceptrin 0
                    Ser-Tyr 0
                    THZ531 0
                    TMC-1A 0
                    TMC-1B 0
                    TMC-1C 0
                    TMC-1D 0
                    VPC 23019 0
                    WIN 18446 2
                    XV638 0
                    [6)-alpha-D-Glcp-(1->4)-alpha-D-NeupAc-(2->]n 0
                    acedapsone 0
                    acyl-CoA + 28
                    adipiodone 0
                    afatinib + 8
                    alpha-N-dichloroacetyl-p-aminophenylserinol 0
                    alpha-hydroxyhippuric acid 0
                    arterolane 0
                    asukamycin 0
                    aureothricin 0
                    benthiavalicarb-isopropyl 0
                    beta-D-glucosyl-(1<->1')-N-eicosanoylsphinganine 0
                    beta-sanshool 0
                    betrixaban 0
                    bistratamide I 0
                    cadabicine sulfate 0
                    carboxin 0
                    cefcapene 0
                    celacinnine 0
                    cenicriviroc 0
                    chlorantraniliprole 0
                    cinanserin 0
                    cinromide 0
                    cladoniamide D 0
                    cladoniamide E 0
                    cladoniamide F 0
                    cladoniamide G 0
                    colibactin 0
                    cyantraniliprole 0
                    cyclobutrifluram 0
                    cyproflanilide 0
                    cystodytin D + 0
                    cystodytin E + 0
                    cystodytin F 0
                    cystodytin G 0
                    cystodytin H 0
                    cystodytin I 0
                    dacomitinib 1
                    dalfopristin 0
                    dapdiamide A 0
                    dapdiamide B 0
                    dapdiamide C 0
                    dichotomide V 0
                    dimethyloxalylglycine 0
                    eribaxaban 0
                    fenpicoxamid 0
                    florfenicol 0
                    florylpicoxamid 0
                    fusarithioamide A 0
                    gamma-Glu-Tyr 0
                    gamma-glutamyl-beta-aminopropiononitrile 0
                    gamma-sanshool 0
                    homoplatensimide A methyl ester 0
                    hookerianamide J 0
                    idrocilamide 0
                    isariotin F 0
                    ivosidenib 0
                    jawsamycin 0
                    kalimantacin B 0
                    marimastat 7
                    methfuroxam 0
                    methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate 0
                    mivotilate 0
                    monepantel 0
                    monoacetyldapsone 0
                    morinamide 0
                    nilotinib 52
                    osimertinib 13
                    pavinetant 0
                    pederin 0
                    pepstatin A 18
                    pilsicainide 0
                    pipercallosidine 0
                    pipercallosine 0
                    pisoniamide 0
                    platencin A1 methyl ester 0
                    platencin A2 methyl ester 0
                    platencin A3 methyl ester 0
                    platensimycin A1 methyl ester 0
                    pristinamycin IIA + 0
                    protoasukamycin + 0
                    pyrrolysine + 0
                    rac5c 0
                    salicyluric acid + 1
                    salubrinal 52
                    sapacitabine 0
                    saponaceol A 0
                    somocystinamide A 0
                    sphingomyelin + 0
                    suramin 31
                    syncarpamide 0
                    teriflunomide 40
                    tert-butyl N-\{1-[(1S)-1-\{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl\}-2-cyclopropylethyl]-2-oxopyridin-3-yl\}carbamate 0
                    tetrachlorantraniliprole 0
                    tetraniliprole 0
                    tranilast 5
                    tromantadine 0
                    tyrphostin B42 1
                    vibegron 0
                    vibriobactin + 0
                    ximelagatran 1
                    ximelagatran (hydroxylamine form) 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      carbon group element atom 19608
                        carbon atom 19597
                          organic molecular entity 19597
                            organic group 18537
                              organic divalent group 18530
                                organodiyl group 18530
                                  carbonyl group 18436
                                    carbonyl compound 18436
                                      carboxylic acid 18114
                                        carboacyl group 17372
                                          univalent carboacyl group 17372
                                            carbamoyl group 17158
                                              carboxamide 17158
                                                secondary carboxamide 268
                                                  (-)-Jasmonoyl-L-isoleucine 0
                                                  (1R)-Hydroxy-(2R)-N-acetyl-L-cysteinyl-1,2-dihydronaphthalene 0
                                                  (1R)-N-Acetyl-L-cysteinyl-(2R)-hydroxy-1,2-dihydronaphthalene 0
                                                  (1S)-Hydroxy-(2S)-N-acetyl-L-cysteinyl-1,2-dihydronaphthalene 0
                                                  (2E,24R)-24-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-2-methylpentacos-2-enamide 0
                                                  (2R)-N-[(2S)-3,3-dimethyl-1-oxo-1-[[(1R)-1-phenylethyl]amino]butan-2-yl]-N'-hydroxy-2-[3-(3-methyl-4-phenylphenyl)propyl]butanediamide 0
                                                  (2S)-2-[[(2-chlorophenyl)-oxomethyl]amino]-3-methylbutanoic acid (3-cyano-4-imino-2-oxopentyl) ester 0
                                                  (2S)-2-[[(2-chlorophenyl)-oxomethyl]amino]-3-methylbutanoic acid (6-nitro-4H-1,3-benzodioxin-8-yl)methyl ester 0
                                                  (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-phenylacetic acid cyclopentyl ester 0
                                                  (2S)-2-[[(2S)-2-[(2S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                                                  (2S)-2-[[(2S)-2-[(2S,3R)-2-[(2-amino-3-mercaptopropyl)amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                                                  (2S)-2-[[2-[(2S,3S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                                                  (2S)-2-[[[5-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]propanoic acid tert-butyl ester 0
                                                  (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                                                  (2S)-2-acetamido-3-(1H-indol-3-yl)propanamide 0
                                                  (2S)-3-methyl-2-[[(3-methylphenyl)-oxomethyl]amino]butanoic acid (4-oxo-2-pyrimido[2,1-b][1,3]benzothiazolyl)methyl ester 0
                                                  (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                                                  (2S,3S,4R)-4-cyclopropyl-2-ethoxy-3-(3-hydroxypropyl)-N-prop-2-ynyl-3,4-dihydro-2H-pyran-6-carboxamide 0
                                                  (6R,7R)-7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 0
                                                  (R)-N-trans-feruloyloctopamine 0
                                                  (Z)-N-cyclopropyl-11-methyldodec-2-enamide 0
                                                  (Z)-N-cyclopropyldodec-2-enamide 0
                                                  1-amino-15-oxo-4,7,10-trioxa-14-azaoctadecan-18-oic acid 0
                                                  1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-N-[4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]-1,4-dihydroquinoline-3-carboxamide 0
                                                  2,2,2-trideuterio-N-[1,1,2,2-tetradeuterio-2-(5-hydroxy-1H-indol-3-yl)ethyl]acetamide 0
                                                  2,2,2-trifluoro-N-(2-methyl-8-quinolinyl)acetamide 0
                                                  2,2,2-trifluoro-N-(5-oxo-1-phenyl-4H-pyrazol-3-yl)acetamide 0
                                                  2,2,2-trifluoro-N-(8-hydroxyoctyl)acetamide + 0
                                                  2,2,2-trifluoro-N-[2-(1H-indol-3-yl)ethyl]acetamide 0
                                                  2,9-dideoxy-9-glutaramido-2,3-dehydo-N-acetylneuraminic acid 0
                                                  2-(1H-benzimidazol-2-yl)-N-(2-furanylmethyl)-3-[3-(trifluoromethyl)phenyl]-2-propenamide 0
                                                  2-(2,4-dioxo-1H-pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]acetamide 0
                                                  2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[2-[[3-(2-chlorophenyl)-1-oxoprop-2-enyl]amino]-4-thiazolyl]acetic acid ethyl ester 0
                                                  2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid 0
                                                  2-[[1-oxo-3-(4-pentylphenyl)prop-2-enyl]amino]benzoic acid 0
                                                  2-[[2-(3,4-dimethoxyanilino)-2-oxoethyl]thio]-3-pyridinecarboxylic acid propan-2-yl ester 0
                                                  2-[[2-cyano-3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]-4-phenyl-3-thiophenecarboxylic acid ethyl ester 0
                                                  2-[[3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid 0
                                                  2-[[3-(4-methoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid 0
                                                  2-[[oxo(thiophen-2-yl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester 0
                                                  2-\{[2-(2-chlorophenyl)-2-hydroxyethyl]amino\}-N-[(2-fluorophenyl)methyl]acetamide 0
                                                  2-chloro-N-(4-fluorophenyl)-3-phenyl-2-propenamide 0
                                                  2-chloro-N-[2-[2-[(5-chloro-3-methyl-1-phenyl-4-pyrazolyl)methylidene]hydrazinyl]-2-oxoethyl]benzamide 0
                                                  2-chloro-N-[2-[2-[(5-nitro-2-thiophenyl)methylidene]hydrazinyl]-2-oxoethyl]benzamide 0
                                                  2-cyano-3-(1,3-dimethyl-2-oxo-5-benzimidazolyl)-N-(4-methoxyphenyl)-2-propenamide 0
                                                  2-cyano-3-(4,5-dimethoxy-2-nitrophenyl)-N-(2-oxolanylmethyl)-2-propenamide 0
                                                  2-cyano-N-(2-methoxyphenyl)-3-[5-nitro-2-(1-pyrrolidinyl)phenyl]-2-propenamide 0
                                                  2-cyano-N-(3-methylphenyl)-3-[4-(methylthio)phenyl]-2-propenamide 0
                                                  2-cyano-N-(4-ethoxyphenyl)-3-[3-methyl-4-(1-pyrrolidinyl)phenyl]-2-propenamide 0
                                                  2-cyano-N-[3-(1-imidazolyl)propyl]-3-(4-nitrophenyl)-2-propenamide 0
                                                  2-cyano-N-cyclohexyl-3-[4-(methylthio)phenyl]-2-propenamide 0
                                                  2-methyl-N-(6-nitro-1,3-benzothiazol-2-yl)-3-phenyl-2-propenamide 0
                                                  3',4'-difluoro-N-\{4'-fluoro-6-[(3S)-pyrrolidin-3-yloxy][biphenyl]-3-yl\}-6-[(3S)-pyrrolidin-3-yloxy][biphenyl]-3-carboxamide 0
                                                  3-(1,3-benzodioxol-5-yl)-2-cyano-N-(4-hydroxyphenyl)-2-propenamide 0
                                                  3-(1,3-benzodioxol-5-yl)-N-(4-phenyl-2-thiazolyl)-2-propenamide 0
                                                  3-(1,3-benzodioxol-5-yl)-N-[2-(4-methylphenyl)-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]-2-propenamide 0
                                                  3-(1,3-benzodioxol-5-yl)-N-[2-[(4-chlorophenyl)methylthio]ethyl]-2-propenamide 0
                                                  3-(2,4-dimethylphenyl)-N-(thiophen-2-ylmethyl)-2-propenamide 0
                                                  3-(2-chloro-6-fluorophenyl)-N-pyridin-4-yl-2-propenamide 0
                                                  3-(2-chlorophenyl)-N-[4-(dimethylsulfamoyl)phenyl]-2-propenamide 0
                                                  3-(2-chlorophenyl)-N-pyridin-4-yl-2-propenamide 0
                                                  3-(2-nitrophenyl)-N-(3-pyridinyl)-2-propenamide 0
                                                  3-(3-anilino-3-oxoprop-1-enyl)-N-hydroxybenzamide 0
                                                  3-(4-chlorophenyl)-N-(3-methoxyphenyl)-2-propenamide 0
                                                  3-(4-fluorophenyl)-N-(6-methoxy-3-pyridinyl)-2-propenamide 0
                                                  3-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)-2-propenamide 0
                                                  3-(4-methoxyphenyl)-N-(11-oxo-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-2-yl)-2-propenamide 0
                                                  3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propenamide 0
                                                  3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide + 0
                                                  3-[3-[(2-bromo-4-chlorophenoxy)methyl]-4-methoxyphenyl]-N-[(1,3-dimethyl-4-pyrazolyl)methyl]-2-propenamide 0
                                                  3-amino-6-chloro-5-(dimethylamino)-N-(3-pyridinyl)-2-pyrazinecarboxamide 0
                                                  3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide 0
                                                  3-bromo-N-\{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl\}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide + 0
                                                  3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}-L-phenylalaninamide 0
                                                  3-methyl-2-[[oxo-(4-pentoxyphenyl)methyl]amino]butanoic acid 0
                                                  3-phenyl-N-(3-pyridinyl)-2-propenamide 0
                                                  3-phenyl-N-[2,2,2-trichloro-1-[[(8-quinolinylamino)-sulfanylidenemethyl]amino]ethyl]-2-propenamide 0
                                                  4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide 0
                                                  4-(2,6-difluorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide 0
                                                  4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide 0
                                                  4-[[(4-bromo-2-ethyl-3-pyrazolyl)-oxomethyl]amino]benzoic acid propan-2-yl ester 0
                                                  4-[[2-furanyl(oxo)methyl]amino]benzoic acid propan-2-yl ester 0
                                                  4-[[4-[2-cyano-3-(4-methoxyanilino)-3-oxoprop-1-enyl]-2-methoxyphenoxy]methyl]benzoic acid 0
                                                  4-chloro-N-[1-[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-3-methyl-1-oxobutan-2-yl]benzamide 0
                                                  4-chloro-N-[3-(3-methylanilino)-1-(5-nitro-2-furanyl)-3-oxoprop-1-en-2-yl]benzamide 0
                                                  4-hydroxyprotoasukamycin + 0
                                                  4-methylbenzenesulfonic acid [4-(3-amino-2-cyano-3-oxoprop-1-enyl)-2-methoxyphenyl] ester 0
                                                  5-(3-azidopropylamino)-5-oxopentanoic acid + 0
                                                  5-(4,6-dioxo-3-propan-2-yl-1-cyclohex-2-enylidene)-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-2H-isoxazole-3-carboxamide 0
                                                  5-[[3-(1,5-dimethyl-4-pyrazolyl)-1-oxoprop-2-enyl]amino]-3-methylthiophene-2,4-dicarboxylic acid O2-ethyl ester O4-propan-2-yl ester 0
                                                  ANA-12 0
                                                  Arachidonoyl dopamine 0
                                                  Asn-Ile 0
                                                  BMS 195614 0
                                                  Butoctamide hydrogen succinate 0
                                                  CDN1163 0
                                                  CX-5461 0
                                                  Capsi-amide 0
                                                  Cuscuta propenamide 1 0
                                                  Cuscuta propenamide 2 0
                                                  Cyanthoate 0
                                                  Cys-Ser 0
                                                  DEL-22379 0
                                                  EI-1511-3 0
                                                  Fagaramide 0
                                                  LGK974 7
                                                  LSM-14399 0
                                                  LSM-17442 0
                                                  LSM-4709 0
                                                  LSM-9991 0
                                                  LimKi 3 0
                                                  MI-63 0
                                                  MMP-9-IN-1 0
                                                  N(1),N(8)-bis(coumaroyl)spermidine 0
                                                  N(1),N(8)-bis(sinapoyl)-spermidine 0
                                                  N(1),N(8)-bis-(dihydrocaffeoyl)spermidine 0
                                                  N(2)-(3-hydroxy-3-methylhexanoyl)-L-glutamine 0
                                                  N(2)-[(2E)-3-methylhex-2-enoyl]-L-glutamine 0
                                                  N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-3,3-dimethoxyalaninamide 0
                                                  N(2)-[4-(indol-3-yl)butanoyl]-L-glutamine 0
                                                  N(3)-fumaramoyl-(S)-2,3-diaminopropanoic acid 0
                                                  N(3)-fumaroyl-(S)-2,3-diaminopropanoic acid 0
                                                  N(4)-acetyl-2'-deoxycytidine 0
                                                  N(4)-acetylcytidine 0
                                                  N(6)-trifluoroacetyl-L-lysine 0
                                                  N,N',N''-tris(3-pyridyl)benzene-1,3,5-tricarboxamide 0
                                                  N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                                                  N,O-diacylethanolamine + 0
                                                  N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                                                  N-(1-phenylethyl)acetamide + 0
                                                  N-(11-oxo-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-2-yl)-3-(3,4,5-trimethoxyphenyl)-2-propenamide 0
                                                  N-(2-anilino-2-oxoethyl)-2-methoxybenzamide 0
                                                  N-(2-hydroxydocosanoyl)eicosasphinganine 0
                                                  N-(2-hydroxyhexacosanoyl)phytosphingosine + 0
                                                  N-(3-anilino-3-oxo-1-phenylprop-1-en-2-yl)benzamide 0
                                                  N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide 0
                                                  N-(3-methoxyphenyl)-3-(4-nitrophenyl)-2-propenamide 0
                                                  N-(3-oxohexanoyl)homoserine lactone 0
                                                  N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                                                  N-(4-carboxy-4-oxobutanoyl)-L-ethylglycylglycine 0
                                                  N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)-1-(N,N-dimethylglycyl)piperidine-4-carboxamide 0
                                                  N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)-2-(4-methylpiperazin-1-yl)pyridine-4-carboxamide 0
                                                  N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0